Document:

EX-10.4

 Exhibit 10.4 

CONFIDENTIAL 
 CERTAIN CONFIDENTIAL
PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED.

 BIOLOGICS MASTER SERVICES AGREEMENT 

This Master Services Agreement (this “Agreement”) is dated March 22, 2017 (the “Effective Date”) and is between iTeos
Therapeutics SA (“Client”) and WuXi Biologics (Hong Kong) Limited (“Provider”). 
  

	A.	 Client discovers and develops biologics. 

 

	B.	 Provider coordinates the biologics development and manufacturing services that are provided by certain
affiliated operating companies. 

  

	C.	 The parties desire that one or more of Provider and/or its Affiliates provide services to Client on a project-by-project basis. The services for each project (the “Services;’) will be provided pursuant to a separate and distinct contract (a “Work
Order”) that incorporates the terms of this Agreement. 

 The parties therefore agree as follows: 

 

	1.	 DEFINITIONS 

  

	1.1	 “Affiliate” of a person means any other person that directly or indirectly Controls, is
controlled by, or is under common Control with, the person. 

  

	1.2	 “Applicable Law” means all applicable laws, regulations and cGMP and other official guidelines
and directives relevant to the activities performed under this Agreement and the supply, use, marketing or sale of the Product. 

  

	1.3	 “Cell Line” means the cell line that has been developed to produce Product.

  

	1.4	 “Certificate of Analysis” means a document setting out the results of analysis of a batch of
Product together with the Specifications and methods by which the tests were performed, in a form agreed to by the parties. 

  

	1.5	 “cGMP” means current Good Manufacturing Practices (a) as promulgated under 21 C.F.R.
Parts 210 and 211, as the same may be amended or re-enacted from time to time and (b) as required by Applicable Law in countries other than the United States where pharmaceutical product manufacturing is
conducted. 

  

	1.6	 “Confidential Information” of a party (the “Disclosing Party’;) means all
information and materials disclosed by or on behalf of the party to the other party (the “Receiving Party”) or its Related Persons in connection with this Agreement. The Confidential Information of both parties includes the
existence, terms and objectives of this Agreement, and the nature of any dispute and the outcome of any arbitration proceedings arising out of or in connection with this Agreement. 

  
 1 

	1.7	 “Control” over a person means (a) owning 50% or more of the voting securities or other
ownership interests of the person or (b) having the power to direct the management or policies of the person. 

  

	1.8	 “Intellectual Property” means patents and patent applications, trademarks, trade names,
service marks, domain names, copyrights and copyright applications and registrations, schematics, industrial models, inventions, know-how, trade secrets, computer software programs and other intangible
proprietary Information. 

  

	1.9	 “Product” means the product, or a part or derivative of the product, that is manufactured
through the Services or to be produced by a Cell line. 

  

	2.	 SERVICES 

  

	2.1	 Work Orders. Provider shall provide the Services to Client pursuant to each Work Order that is entered
into during the term of this Agreement. The preferred form of Work Order is provided in Exhibit A. The initial Work Order, titled “Mab CMC Development and Manufacturing Contract Services Proposal for iTeos”, has been executed by the
parties as of the date hereof and is attached hereto as Appendix 1. Each Work Order will automatically incorporate the terms of this Agreement and be an integral part of this Agreement. If there is a contradiction between a provision of this
Agreement and a Work Order, then the provision in this Agreement will take precedence unless the Work Order specifically states that it takes precedence over the provision. 

 

	2.2	 Manufacturing. Certain manufacturing terms are provided in Exhibit Band are an integral part of
this Agreement and the Services. 

  

	2.3	 Services and Deliverables. With respect to any Services or deliverables other than the manufacture of
Products, the following shall apply: 

 (a) Provider warrants to Client that the Services and each deliverable provided to
Client under a Work Order will be performed and provided in accordance with, and will comply with, this Agreement, the relevant Work Order(s), all applicable specifications, cGMP (if applicable) and Applicable Law (the “Services
Warranty”). If a timeline for the performance of Services is specified in a Work Order, Provider agrees to provide the Services in accordance with such timeline. 

(b) Client shall have [***] after Provider has completed a particular Service or delivered a particular deliverable to review such Service or
deliverable to assess whether it meets the Services Warranty. If Client determines that a particular Service or deliverable does not meet the Services Warranty, Client will notify Provider in writing

  
 2 

 
thereof within such [***] period. If Provider does not provide written notice to Client disputing such determination by Client within [***] of receipt of Client’s notice, then Provider will
be deemed to have agreed to Client’s determination. Acceptance of a Service or deliverable shall not be deemed to constitute a waiver by Client of any rights it may have based on Provider’s warranties. 

(c) If the parties are unable to agree as to whether a particular Service or deliverable conforms to the Service Warranty, Client shall have
the right to retain an independent expert that is reasonably acceptable to Client to make such assessment. The findings of the independent expert will be binding on the parties. The cost of such expert will be borne equally by each party. 

(d) [***] 
  

	2.4	 Subcontracting; Affiliates 

 

	 	(a)	 Provider may delegate or subcontract the Services to an Affiliate. If the Services are provided by an
Affiliate, then references to Provider in this Agreement will be deemed to be references to the Affiliate with the necessary modifications. Provider shall be liable for the performance of the Affiliate to the same extent as if the performance was
that of Provider. 

  

	 	(b)	 Provider may not delegate or subcontract the Services to any third party (excluding Affiliates pursuant to
Section 2.4(a)) without Client’s prior written consent. If Client grants such consent, Provider shall be liable for the performance of the third party subcontractor to the same extent as if the performance was that of Provider.

  

	 	(c)	 An Affiliate of a party may enter into a Work Order instead of the party. If a Work Order is entered into by an
Affiliate, then references to the party in this Agreement will be deemed to be references to the Affiliate with the necessary modifications. The party shall be liable for the performance of the Affiliate to the same extent as if the performance was
that of the party. 

  

	3.	 SERVICE FEE; PAYMENT 

 

	3.1	 Service Fee. Client shall pay Provider a service fee in the amount and manner provided in the applicable
Work Order (the “Service Fee”). The Service Fee may be charged in accordance with a lump-sum or other pricing structure agreed to by the parties. A lump-sum Service Fee is a fixed amount based
on the estimated cost of the Services. The actual cost may differ from the estimated cost as and to the extent specified in each applicable Work Order. 

  
 3 

	3.2	 Expenses. Client shall reimburse Provider for reasonable expenses that are (a) specifically
authorized by Client in writing, (b) specifically agreed in the applicable Work Order, or (c) specifically agreed in this Agreement, including Sections 4.4, 5.1, 5.2, 5.3, 7.l(b), 9.3 and 12 and paragraphs 1.3 and 2.2 of Exhibit B.

  

	3.3	 Milestones. If a Work Order includes a payment for completion of a project stage or other kind of
milestone, then Provider shall notify Client promptly after the milestone is achieved. Client will be deemed to have agreed that the milestone was achieved unless it notifies Provider otherwise within [***] or a longer period if so provided in a
Work Order, Section 2.3 or Exhibit B. Each milestone payment is designed to reflect fair value of the corresponding Services, and is not dependent on any other milestone unless otherwise specified in the Work Order.

  

	3.4	 Payment. Client shall pay each of Provider’s invoices within [***] of receipt by wire transfer to
the account designated by Provider. Except as provided in this Agreement or a Work Order, payment must be made without set-off or other deduction of any nature. The Service Fee is exclusive of, and Client
shall pay, any applicable taxes (other than taxes on Provider’s income and franchise taxes) and other fees of any nature imposed by or under the authority of any government authority with respect to the Service Fees paid by Client to Provider.

  

	3.5	 No Clawbacks. Except as provided in this Agreement or a Work Order, Service Fee and other payments under
this Section are non-cancelable and non-refundable. 

  

	3.6	 Payment Default. In the event of an overdue payment (a “Payment Default”),(a) interest
of [***] will be accrued [***] of the overdue payment as of the date of the Payment Default and (b) Provider may suspend the provision of the Services until the Payment Default is rectified by Client. If the Payment Default is not rectified
within [***] after receipt by Client of written notice of the Payment Default, then it will be deemed an incurable material breach of the applicable Work Order, and Provider may terminate the Work Order pursuant to Section 11.2(b).

  

	3.7	 Annual Review. At [***] each party to a Work Order may propose a. prospective adjustment of the Service
Fee to reflect changes in the following pricing: factors (a) cost reductions and efficiency increases, (b) inflation or deflation, and (c) documented changes in the price of raw materials charged by third parties. The parties shall
negotiate in good faith with the aim of identifying a mutually acceptable amendment of the Work Order. 

  
 4 

	4.	 PROVISION OF SERVICES 

 

	4.1	 Specifications. Provider shall provide the Services in accordance with the specifications of the
applicable Work Order. 

  

	4.2	 Qualifications. Provider shall ensure that the persons that provide the Services (the
“Personnel”) (a) have the appropriate skills, training and experience and (b) are bound by confidentiality obligations consistent with the terms of this Agreement. 

 

	4.3	 Compliance. Provider shall provide the Services in compliance with Applicable Law, c.GMP and all other
applicable GxP in all material respects. 

  

	4.4	 On-Site Monitoring. Representatives of Client may, upon
reasonable notice during Provider’s normal business operating hours, visit the facilities where the Services are provided and consult informally during such visits with appropriate Personnel in order to monitor the Services. The representatives
will be bound by rules applicable to the facilities that are provided to Client in writing in advance of any visit and may, at the reasonable discretion of Provider, be given limited access to certain areas within the facilities to the extent
necessary to protect confidential information of Provider’s other clients. Provider may require that Client or the representatives execute an agreement, in a form reasonable and customary for the industry, that regulates the
representatives’ conduct during their visit. Client shall be responsible for all of its expenses incurred in connection with such visits. 

  

	5.	 SOURCING OF MATERIAL 

 

	5.1	 Materials. Provider shall, except as otherwise specified in the applicable Work Order, purchase all
materials necessary for the Services (the “Materials”), and the party responsible for paying for such materials shall be specified in the Work Order (and if not specified, Provider shall be the responsible party). If a Material is
not commercially available, then Client may elect to (a) supply, at its expense, the Material to Provider; Provider shall do the market research and propose a name list of vendors in compliance with Applicable Law and applicable cGMP and other
GxP in all material respects. Provider shall take the inventory risk of the selected materials, including for damage caused by improper storage or pollutions; or (b) amend the applicable Work Order to permit the use of a commercially available
substitute. 

  

	5.2	 Client Materials. If a Material is to be supplied by Client as specified in the applicable Work Order (a
“Client Material”), then Client shall provide the Client Material at its expense in a timely manner and provide such information as may be required by Provider or Applicable Law concerning the stability, storage and safety
requirements. Provider shall ensure that the Client Material will be (a) used solely for the purpose of providing the Services, (b) only distributed to Personnel on a
need-to-know basis for the provision of the Services, (c) be kept free of all liens, claims and encumbrances arising from acts or omissions of Provider, and
(d) preserved and protected in a manner consistent with the 

  
 5 

	 	specifications of the applicable Work Order, cGMP and any relevant standard operating procedures or other instructions provided by Client. The parties acknowledge and agree that title to Client Materials shall at all
times belong to and remain the property of the Client. Provider shall notify Client promptly of any damage to or destruction of Client Materials, and shall compensate Client for any Client Materials lost, destroyed or damaged during Provider’s
storage. 

  

	5.3	 Unused Client Materials and Other Materials. Provider shall, at Client’s option and expense,
return, destroy or otherwise dispose of unused Client Materials and any Materials for which Client has paid, promptly after the earlier of (a) completion of the Services for which the Client Materials were provided, (b) termination of the
applicable Work Order, or (c) receipt of written instructions from Client pertaining to their disposition. Provider may dispose of other unused Materials at its sole discretion. 

 

	6.	 RECORDS 

  

	6.1	 Storage. All materials, data and documentation obtained or generated by Provider in the course of
providing the Services, including all computerized records and files (“Records”), will be maintained in a secure area in accordance with industry standards, cGMP and Applicable Law. The Records are the sole and exclusive property of
Client. 

  

	6.2	 Retention. Upon termination of the applicable Work Order, Provider shall, at Client’s option,
(a) destroy the Records, (b) deliver the Records to Client, or (c) retain the Records for [***] and then destroy them. If the Records are to be destroyed, then Provider shall give [***] written notice to Client, and Client may
elect during the [***] period to have the Records transferred to it. Notwithstanding the foregoing, the Records may be retained as required by Applicable Law or as otherwise necessary for regulatory or insurance purposes. 

 

	7.	 INTELLECTUAL PROPERTY 

 

	7.1	 Ownership 

  

	 	(a)	 Except as otherwise provided in this Agreement, (i) Provider has no rights in any Intellectual Property
that is owned by or licensed to Client or any of its Affiliates independently of this Agreement (“Client IP”) and (ii) Client has no rights in any Intellectual Property that is owned by or licensed to Provider or any of its
Affiliates independently of this Agreement (“Provider IP”). 

  

	 	(b)	 Provider shall ensure that each of the Personnel vests in Provider any and all rights that such person might
otherwise have in the Intellectual Property created or developed in connection with the provision of the Services (“Project IP”). Provider hereby assigns and shall assign all right, title and interest in Project IP to Client. Client
will, at its expense, have sole control offiling and prosecuting applications for, 

  
 6 

	 	
and maintenance and enforcement bf, patents for Project IP. Provider shall, at Client’s expense, use reasonable efforts to assist Client to obtain, maintain and enforce the patents.
Client shall promptly notify Provider of any patents granted for Project IP. Provider is responsible for all payments to be made to Personnel in accordance with Applicable Law requiring remuneration for inventions. 

 

	 	(c)	 Notwithstanding the foregoing, Intellectual Property created or developed in connection with the provision of
the Services (i) that is solely a derivative of Provider IP, (ii) that solely relates to experimental methods, or (iii) that solely relates to manufacturing processes developed at Provider’s expense (“Manufacturing
Improvements”) is Provider IP and not Project IP. 

  

	7.2	 General Licenses 

 

	 	(a)	 Client hereby grants, and shall ensure that each applicable Affiliate will promptly grant, to Provider and its
Affiliates the limited, non-exclusive, non-sublicensable and non-transferable right to use Client IP and Project IP for the
purpose of providing the Services to Client and its Affiliates. 

  

	 	(b)	 Provider hereby grants, and shall ensure that each applicable Affiliate will promptly grant, to Client and its
Affiliates the limited, non-exclusive, worldwide, perpetual, irrevocable, non-terminable, royalty-free and fully paid-up right
and license to use Provider IP and Manufacturing Improvements for the purpose of using Project IP and manufacturing or having manufactured the Product. Upon Client’s request, Provider promptly shall disclose to Client and provide written
documentation to Client specifying in reasonable detail the Project IP and Manufacturing Improvements. 

  

	7.3	 CHO Kl-Cell Line License. If Client agrees to use
Provider’s CHO Kl-Cell Line (the “Cell Line”) for the manufacture of Product, then Client shall purchase a worldwide, fully paid-up, sublicensable, exclusive license to research, develop, make,
have made, and commercialize the Product (the “License”) no later than the Client’s initiation of manufacturing of materials to support IND Filing for such Product. Client shall request a License in writing, then the License shall be
deemed to be granted by Provider to Client and the parties shall enter into a license agreement (“License Agreement”) on commercially reasonable terms agreed by the parties in good faith to finalize the license. [***] Provider has the full
right, power and authority to grant all of the right, title and interest in the license granted under this Section. Under no circumstances, would Client be allowed to perform any cell line engineering activities, such as over express, delete or
modify any genes, or genome sequences on cell lines developed by Provider. 

  
 7 

	7.4	 CHO Kl-Cell Line Royalties. If Client manufactures all of its
commercial supplies of the Product by a manufacturer other than Provider or its Affiliates, Client shall pay to Provider, at Client’s election, (a) a Royalty of [***] on the Product’s global sales, paid to Provider quarterly, or
(b) a one-time milestone payment equal to [***] payable within [***] after receipt by Client of regulatory approval of a Biologicals License Application for the Product in the first of the [***] [***]

  

	8.	 REPRESENTATIONS AND WARRANTIES 

 

	8.1	 Mutual. Each party represents and warrants that (a) it validly exists under the laws of the
jurisdiction in which it was organized, (b) it has the full power, right and authority to execute and deliver this Agreement and to perform its obligations under this Agreement, (c) this Agreement once executed will constitute a legal, valid
and binding agreement enforceable against it and (d) its performance of this Agreement will not conflict with any obligations it may have to any other person. 

 

	8.2	 Infringement. Each party represents and warrants that, to the best of its knowledge, the Services will
not infringe the Intellectual Property rights of any third party. 

  

	8.3	 Debarment. Provider represents and warrants that neither it nor any of the Personnel has been debarred,
or, to the best of its knowledge, is under consideration for debarment, by the United States Food and Drug Administration from working in or providing services to any pharmaceutical or biotechnology company pursuant to the Generic Drug Enforcement
Act of 1992 or any other governmental authority pursuant to analogous laws. Provider represents and warrants that it does not currently have,. and covenants that it and its Affiliates will not hire, as an officer or an employee any person who has
been convicted of a felony under the laws of the United States for conduct relating to the regulation of any drug product under the Federal Food, Drug, and Cosmetic Act (United States). 

 

	8.4	 Compliance with Law. Each party (a) represents and warrants that neither it nor any of its
Affiliates violated any Applicable Law in connection with actions leading up to entry into this Agreement or any Work Order and (b) shall, and shall ensure that each applicable Affiliate will, comply with all Applicable Law in connection with
performance of this Agreement and any Work Orders. Each party shall immediately notify the other party upon becoming aware of a breach of this Section. Breach of this Section with respect to the U.S. Foreign Corrupt Practices Act or any other
anti-bribery law will be deemed an incurable material breach for purposes of Section 11.2(b). 

  
 8 

	8.5	 Services. Provider represents and warrants that (a) it has no knowledge of any claims, actions or
other actual or threatened legal proceedings or investigations by any governmental or regulatory authority, the subject of which is (i) the infringement, violation or misuse of third party rights by any Provider IP, or (ii) the violation
of Applicable Law by Provider or the facilities at which the Services will be performed; (b) all Product provided to Client shall have been manufactured in accordance with, and will conform with, the Quality Agreement, the applicable
specifications), cGMP and Applicable Law, and shall at the time of delivery to Client meet all specifications and not be adulterated, misbranded or mislabeled within the meaning of Applicable Laws; (c) all Product delivered to Client will be
free and clear of liens, claims and encumbrances, excluding claims for payments due from Client to Provider in respect of such Product; (d) the facilities utilized by Provider or its Affiliates or permitted third party subcontractors are
registered with the appropriate governmental and regulatory authorities and in compliance with all Applicable Laws as they relate to the Services for the Product; and (e) it will maintain at all relevant times all governmental permits,
licenses, approval, and authorities required to enable it to lawfully and properly perform the Services. 

  

	9.	 INDEMNIFICATION; LIMITATION ON LIABILITY; INSURANCE 

 

	9.1	 Third Party Claims. Each party shall defend, indemnify and hold the other party and its Affiliates and
its and their directors, officers, employees, agents and consultants and legal, financial, accounting and other advisors (“Related Persons”) harmless from and against any and all liabilities and damages (including reasonable
attorneys’ fees) (“Losses”) resulting from any third party claims, demands, suits or proceedings (“Claims”) to the extent arising out of or relating to (a) in the case that Provider is the indemnifying
party, its performance of the Services, (b) in the case that Client is the indemnifying party, its use of Project IP or deliverables produced under a Work Order, (cl a material breach of this Agreement by the indemnifying party, (d) a
material violation of Applicable Law by the indemnifying party or any of its Related Persons or (e) the negligence, recklessness or willful misconduct of the indemnifying party or any of its Related Persons during the course of activities
carried out in connection with this Agreement. The indemnification obligations set forth in this Section 9.1 do not apply to the extent that the Loss arises in whole or in part from the negligence, recklessness or willful misconduct of the
indemnified party or any of its Related Persons. 

  

	9.2	 Intellectual Property Claims. Client shall defend, indemnify and hold Provider and its Related Persons
harmless from and against Losses resultIng from Claims arising out of or related to infringement of any Intellectual Property rights to the extent relating to the Product, other than Claims to the extent based on the Provider IP or any processes or
methods employed by Provider in performing the Services which have not been provided by or are not controlled by Client. Provider shall defend, indemnify and hold Client and its 

  
 9 

	 	
Related Persons harmless from and against Losses resulting from Claims arising out of or related to infringement of any Intellectual Property rights related to the Services and to the extent
based on the on the Provider IP or any processes or methods employed by Provider in performing the Services which have not been provided by or are not controlled by Client. 

 

	9.3	 Defense. Each party shall notify the other party promptly upon learning of a Claim that is subject to
indemnification pursuant to Section 9.1 or 9.2, provided, that the failure of the indemnified party to give such notice shall not relieve the indemnifying party of its obligations under Section 9.1 or 9.2, as applicable, except to
the extent (if any) that the indemnifying party shall have been prejudiced thereby, which notice shall set forth in reasonable detail {A) the facts and circumstances giving rise to such claim for indemnification, including all relevant, reasonably
available, material supporting documentation, (B) the nature of the Losses suffered or incurred or expected to be suffered or incurred, (C) a reference to the provisions of this Agreement in respect of which such losses have been suffered
or incurred or are expected to be suffered or incurred, and (D) the amount of Losses actually suffered or incurred and, to the extent the Losses have not yet been suffered or incurred, a good faith estimate of the amount of losses that could be
expected to be suffered or incurred. The indemnifying party may control, at its own expense, the defense of the Claim in good faith with counsel of its choice as long as such counsel is reasonably acceptable to the indemnified party. The indemnified
party shall use reasonable efforts to cooperate in the defense and may participate at its own expense using its own counsel. No compromise or settlement of any Claim may be made by the indemnifying party without the indemnified party’s written
consent unless [al there is no finding or admission of any violation of law or any violation of the rights of any person and no effect on any other claims that may be made against tire indemnified party, (b) the sole relief provided is monetary
damages that are paid in full by the indemnifying party and no restriction or obligation is imposed on the indemnified party or its Affiliates or their respective assets, and (c) the indemnified party’s rights under this Agreement are not
adversely affected. 

  

	9.4	 Limitations on Liability 

 

	 	(a)	 Except for losses arising from breach of confidentiality obligations or from a party’s gross negligence or
willful misconduct, neither party will be liable to the other party for breach-of-contract damages that constitute consequential, punitive, or special damages.

  

	 	(b)	 Except for Losses arising from breach of confidentiality obligations or from Provider’s gross negligence
or willful misconduct, Provider’s maximum aggregate total liability in connection with a Work Order will not exceed the total payments payable under the Work Order. 

  
 10 

	9.5	 Insurance. Each party shall ensure that insurance coverage is carried and maintained with a financially
sound and reputable insurer against loss from such risks and in such amounts as is sufficient to support its obligations under this Agreement. Each party shall provide a copy of the applicable insurance policy if requested by the other party.

  

	10.	 CONFIDENTIALITY AND PUBLICITY 

 

	10.1	 Confidentiality. Subject to Section 10.2, during the term of this Agreement and for five years
thereafter, the Receiving Party shall, and shall ensure that its Related Persons will, (a) maintain the Confidential Information in confidence, (b) not use the Confidential Information except as strictly necessary to perform its obligations, or
exercise any licenses or similar rights granted, under this Agreement and (c) not disclose the Confidential Information to any third party other than (i) those of its Related Persons that have a need to know the Confidential Information in
connection with the Services and are obligated to maintain the Confidential Information in confidence and (ii) to the extent required by Applicable Law or reasonably necessary to prosecute or defend litigation or arbitration, and, in either
case, only after the Receiving Party gives the Disclosing Party reasonable advance notice of such disclosure (to the extent permitted by Applicable Law) and uses reasonable efforts to secure confidential treatment of the Confidential Information.
Notwithstanding the foregoing, the existence of this Agreement and its non-technical terms may be disclosed confidentially in connection with a potential financing, licensing transaction or acquisition.

  

	10.2	 Exceptions to Confidentiality. The obligations of Section 10.1 do not apply to Confidential
Information if the Receiving Party can demonstrate that (a) the Confidential Information is public knowledge or becomes public knowledge after disclosure through no fault of the Receiving Party or any of its Related Persons, (b) the
Confidential Information was in its or any of its Related Persons’ possession prior to disclosure by the Disclosing Party, (c) the Confidential Information was received from a third party that was not obligated to the Disclosing Party or
any of its Related Persons to maintain the Confidential Information in confidence, or (d) equivalent information was developed independently by the Receiving Party or any of its Related Persons without recourse to the Confidential Information.

  

	10.3	 Return of Confidential Information. Upon termination of this Agreement, and if requested in writing by
the Disclosing Party within [***] thereafter, the Receiving Party shall cause all Confidential Information to be promptly destroyed or returned to the Disclosing Party; provided, however, that (a) the Receiving Party may retain a single secure
copy of any Confidential Information for legal archival purposes, (b) the Receiving Party may retain a reasonable number of copies of any Confidential Information that is reasonably necessary to exercise any licenses or rights granted under
this Agreement that survive termination of this Agreement, (c) the Receiving Party shall be allowed to maintain copies of regulatory documentation or any other materials that contain Confidential Information and which regulatory documentation
or materials are required to be maintained or disclosed by such Receiving Party under Applicable Law, or order of a governmental agency or a court of competent jurisdiction, and (d) electronic back-up
files that have been created by routine archiving and back-up procedures need not be deleted. 

  
 11 

	10.4	 Audits. Provider and its Affiliates may have in the past provided, and may currently or in the future
provide, services to other customers that are similar to the Services. Provider is absolutely committed to protecting its customers’ Intellectual Property and confidential information, and shall not use the Intellectual Property or confidential
information of a customer for the benefit of any person other than the customer. In order to protect the Confidential Information of Client and the confidential information of other customers, Provider shall use reasonable efforts to ensure that
other customers do not seek the disclosure of Confidential Information of Client, and Client shall not seek the disclosure of confidential information of other customers. Notwithstanding the foregoing, if Client wishes to conduct an audit that
relates to services provided to another customer for purposes of confirming that Client’s Intellectual Property and/or Confidential Information -· is adequately protected, then Provider shall use reasonable efforts to seek the other
customer’s approval to waive confidentiality _obligations to the extent necessary to allow Client to conduct the audit in a manner that does not involve disclosure of the other customer’s confidential information to Client. If another
customer wishes to conduct an audit that relates to the Services for purposes of confirming that the other customer’s Intellectual Property is adequately protected, then Client shall permit an independent third party auditor reasonably
acceptable to Client and paid for by the requesting party, to conduct the audit in a manner that does not involve disclosure of Client’s Confidential Information or Intellectual Property to the other customer. 

 

	10.5	 Publicity. Each party shall not, and shall ensure that its Related Persons will not, use the name,
symbols or marks of the other party or any of its Affiliates in any advertising or publicity material or make any form of representation or statement that would constitute an express or implied endorsement by the other party or any of its Affiliates
of any commercial product or service without the other party’s or Affiliate’s prior written consent. 

  

	11.	 TERM AND TERMINATION 

 

	11.1	 Agreement. The term of this Agreement commences on the Effective Date and will terminate one
(1) year after the date on which the last Work Order has expired or been terminated. 

  

	11.2	 Work Orders. The term of each Work Order commences on the date indicated in the Work Order and will
terminate upon completion of the Services under such Work Order. Notwithstanding the foregoing, either party may terminate a Work Order immediately upon written notice to the other party if (a) a material breach of the Work Order by the other
party remains uncured [***] after written notice of the material breach was received by the other party and (bl the material breach was not caused by the party 

  
 12 

	 	
terminating the Work Order or any of its Affiliates. In addition, Client may terminate a Work Order at any time with [***] advance written notice to Provider. If a Work Order is terminated, at
Client’s request, Provider shall permit Client and its designees to access Provider’s facilities, and Provider shall reasonably cooperate with Client and its designees, for purposes of effecting a technology transfer of Client’s
Product and Specifications. 

  

	11.3	 Survival. Upon termination of this Agreement or a Work Order, all outstanding rights and obligations
between the parties arising out of or in connection with this Agreement or the Work Order, as the case may be, will immediately terminate, other than any obligations or rights that (a) matured prior to the effective date of the termination or
(b) by their nature are intended to survive. In addition, Sections 2.3, 3.6, 6, 7, 9, 10, 11.3, 11.4, 11.5, 11.6 and 13 and Exhibit B shall survive termination of this Agreement. Termination of this Agreement for any reason shall not release
either party from any liability or obligation that already has accrued prior to such termination. Termination of this Agreement for any reason shall not constitute a waiver or release of, or otherwise be deemed to prejudice or adversely affect, any
rights, remedies or claims, whether for damages or otherwise, that a party may have hereunder or that may arise out of or in connection with such termination or expiration. 

 

	11.4	 Termination Fee. If a Work Order is terminated, then Client shall pay Provider for the Services rendered
and all non-cancelable obligations in connection with the Services to the extent specified in a Work Order. 

  

	11.5	 Special notes for cancellation of GMP manufacturing. If a notice to cancel GMP manufacturing in the
executed Work Order is received, Provider will try reasonable efforts to find an alternative client to fill the manufacturing slot. In the case where no alterative client can be identified to fill the slot(s), termination charge will be
applied based on the following: 

  

	 	•	 	 [***] termination charge except cost of raw materials purchased by Provider for purposes of Development and
Production under the applicable Work Order, if the cancellation notice is received [***] before the scheduled vial thaw; 

  

	 	•	 	 [***] of GMP batch fee plus cost of raw materials purchased by Provider for purposes of Development and
Production under the applicable Work Order, if the cancellation notice is received [***] before the scheduled vial thaw; 

  

	 	•	 	 [***] of GMP batch fee plus cost of raw materials purchased by Provider for purposes of Development and
Production under the applicable Work Order, if the cancellation notice is received [***] before the scheduled vial thaw; 

  

	 	•	 	 [***] of GMP batch fee plus cost of raw materials purchased by Provider for purposes of Development and
Production under the applicable Work Order, if the cancellation notice is received [***] before the scheduled vial thaw; and 

  
 13 

	 	•	 	 [***] of GMP batch fee plus cost of raw materials purchased by Provider for purposes of Development and
Production under the applicable Work Order, if the cancellation notice is received [***] before the scheduled vial thaw. 

  

	11.6	 Special notes for cancellation of non-GMP manufacturing. If a
notice to cancel non-GMP manufacturing in the executed Work Order is received, Provider will try reasonable efforts to find an alternative client to fill the manufacturing slot. In the case where no alterative
client can be identified to fill the slot(s), termination charge will be applied based on the following: 

  

	 	•	 	 [***] termination charge except cost of raw materials purchased by Provider for purposes of Development and
Production under the applicable Work Order, if the cancellation notice is received [***] before the scheduled vial thaw; 

  

	 	•	 	 [***] of non-GMP batch fee plus cost of raw materials purchased by
Provider for purposes of Development and Production under the applicable Work Order, if the -· cancellation notice is received [***] before the scheduled vial thaw; 

 

	 	•	 	 [***] of non-GMP batch fee plus cost of raw materials purchased by
Provider for purposes of Development and Production under the applicable Work Order, if the cancellation notice is received [***] before the scheduled vial thaw; 

 

	 	•	 	 [***] of non-GMP batch fee plus cost of raw materials purchased by
Provider for purposes of Development and Production under the applicable Work Order, if the cancellation notice is received [***] and 

  

	 	•	 	 [***] of non-GMP batch fee plus cost of raw materials purchased by
Provider for purposes of Development and Production under the applicable Work Order, if the cancellation notice is received [***] 

  

	 	•	 	 [***] of non-GMP batch fee plus cost of raw materials purchased by
Provider for purposes of Development and Production under the applicable Work Order, if the cancellation notice is received [***] 

  

	12.	 SHIPPING 

  

	12.1	 All materials to be provided by Provider to Client will be delivered FCA (carrier named by Client) (lncoterms
2010), including Product and other deliverables produced under a Work Order, returned Client Materials, returned Records and returned Confidential Information. For the avoidance of doubt, FCA (carrier named by Client) means Provider is responsible
for handing over the materials, cleared for export, to a carrier named by Client. Client assumes risk at hand over and pays all costs. 

  

	12.2	 All materials to be provided by Client to Provider will be delivered DDP (site designated by Provider)
(lncoterms 2010), including Materials provided by Client and Client Materials. For the avoidance of doubt, DDP (site designated by Provider) means Client is responsible for delivery to the site designated by Provider and pays all costs including
import duties and taxes, and Provider is responsible for unloading materials from the carrier at its site and assumes risk when materials are made available for unloading at its site. 

  
 14 

	13.	 MISCELLANEOUS 

 

	13.1	 Force majeure. Neither party shall be liable for non-fulfilment
of its obligations under this Agreement if such non-fulfilment is due to an occurrence of: any strikes, labor disputes of whatever nature, other labor disturbances, or lockouts; quarantines or communicable
disease outbreaks; acts of government or state, embargos, or compliance with any order or regulation of any Authority acting within color of right; civil commotion, insurrection, riots, wars, or acts of terrorism; fires, floods, storms, or other
acts of God; interruption of or delay in transportation; lack of, prevention in, or hindrance in obtaining energy, fuel, power, other utilities; failure of suppliers or lack of or inability to obtain components; or any other reason, cause or
contingency beyond the control and without fault or negligence of the party affected thereby (“Force Majeure Event”). If Provider or Client claims a right to excused performance under this Section 13.1, is shall immediately
notify the other party in writing of the extent of its inability to perform, which notice shall specify the Force Majeure Event. Each party shall use reasonable efforts to mitigate adverse consequences resulting from a Force Majeure Event.

  

	13.2	 Assignment. This Agreement may not be assigned by a party without the prior written consent of the other
party; provided, however, that (a) a party may assign this Agreement to an Affiliate with a net worth or insurance commensurate with the obligations to be assumed, and (b) Client may assign this Agreement to a successor to or purchaser of
all or substantially all of its business or assets to which this Agreement relates. Any purported assignment in violation of this Section is void. 

  

	13.3	 Notices. All notices, requests, demands and other communications required under this Agreement must be
in writing and will be deemed to have been given or made and sufficient in all respects when delivered by reputable international courier to the following addresses: 

..... 
 : To Client: 

iTeos Therapeutics SA 
 Rue des
Freres Wright 29 
 B-6041 Gosslies 

, Belgium 
 [•] 

· Attn: [***] 
 : Tel.:
[***] 

  
 15 

			
	 : To Provider:
	  	With a copy to:
	 WuXi AppTec
	  	WuXi Biologics (Hong Kong) Limited
	 Building 1, 288 Fute Zhong Road
	  	Suite 2008, 20/F., Jardine House,1 •
	 · Waigaoqiao Free Trade Zone
	  	Connaught Place, Central, Hong Kong.
	 Shanghai, China 200131
	  	
	 Attn: [***]
	  	
	 Tel.: [***]
	  	

  

	13.4	 Independent Contractor. The parties are independent contractors, and nothing contained in this Agreement
may be deemed or construed to create a partnership, joint venture, employment, franchise, agency, fiduciary or other relationship between the parties. 

  

	13.5	 Non-Solicitation. During the term of this Agreement and for
[***] thereafter, Client shall not induce or solicit (or authorize or assist in the taking of any such actions by any third party) any employee of Provider or any of its Affiliates to leave his or her employment or business association. For purpose
of this Section 13.5, the use of non-targeted employment advertisements and other non-specific recruiting efforts shall not be deemed to be an inducement or solicitation to leave one’s employment or
business association. 

  

	13.6	 Governing Law. The laws of United Kingdom, without giving effect to principles of conflict of laws,
govern all matters relating to this Agreement. 

  

	13.7	 Arbitration. The parties shall engage in good faith consultation to resolve any dispute arising out of
or in connection with this Agreement. Such consultation will begin immediately after one party has delivered to the other party a request for consultation. If the dispute cannot be resolved within [***] following the date on which the request for
consultation is delivered, then either party may submit the dispute to the London Court of International Arbitration (“LCIA “) for arbitration to be conducted in accordance with the LCIA Arbitration Rules in effect at the time of
submission. The place of arbitration will be London, England. The official language of the arbitration will be English. The tribunal will consist of one (1) arbitrator, who will be jointly selected by Client and Provider, provided that if,
within [***] following the date after which the dispute is submitted to the LCIA, the parties cannot agree on a single arbitrator, the arbitration will be heard and determined by three (3) arbitrators, with one arbitrator being appointed by
each party and the third arbitrator being selected by the two party-appointed arbitrators. If either party fails to select an· arbitrator, or if the party-appointed arbitrators cannot agree on a third arbitrator within [***] after the dispute
is submitted to the LCIA, such arbitrator will be appointed by the LCIA. The arbitration proceedings will be confidential, and the arbitrator(s) may issue appropriate protective orders to safeguard each party’s Confidential Information. During
the course of arbitration, the parties shall continue to implement the terms of this Agreement. The arbitral award will be final and binding upon the parties, and the party to the award may 

  
 16 

 apply to a court of competent jurisdiction for enforcement of the award. Each party will
bear its own costs and expenses (including its attorney’s fees) associated with any arbitration initiated under this section; provided that the arbitrator(s) shall assess against the party losing the arbitration all of the arbitrator(s)’
and administrative fees associated with the arbitration, and each party shall otherwise bear its own costs and expenses. Each party hereby submits itself to the jurisdiction of the courts of the place where the arbitration is held, but only for the
entry of judgment with respect to the decision of the arbitrators hereunder. Notwithstanding the foregoing, judgment may be entered to recognize the award (but not to revise or to amend the award) in any court in the country where the arbitration
takes place, or any court having jurisdiction over the parties. Notwithstanding the foregoing, each party has the right to institute an action in a court of proper jurisdiction for injunctive or other equitable relief pending a final decision by the
arbitrator(s). 
  

	13.8	 Entire Agreement; Non-Reliance. This Agreement contains the
entire agreement between the parties with respect to the subject matter of this Agreement. Prior agreements are hereby superseded. For the avoidance of doubt, prior confidentiality obligations are superseded to the extent that they cover
Confidential Information. Each party disclaims that it is relying on any representations or warranties other than those set forth in this Agreement, and irrevocably waives any rights that it might otherwise have to extra-contractual remedies,
including claims in tort relating to communications outside of this Agreement. 

  

	13.9	 Amendment. No modification or waiver of any term of this Agreement or any other form of amendment to
this Agreement will be binding unless made expressly in writing and signed by both parties. An amendment to this Agreement will only be incorporated into Work Orders entered into after the date of the amendment. 

 

	13.10	 No Third Party Beneficiaries. The provisions of this Agreement are for the sole benefit of the parties.

  

	13.11	 Waiver. The waiver by either party of any breach of any term of this Agreement will not constitute a
waiver of any other breach of the same or any other term. Failure or delay on the part of either party to fully exercise any right under this Agreement will not constitute a waiver or otherwise affect in any way the same or any other right.

  

	13.12	 Severability. If any provision in this Agreement is held to be invalid, illegal or unenforceable in any
respect, then (a) the provision will lie replaced by a valid and enforceable provision that achieves as far as possible the intention of the parties and (b) all other provisions of this Agreement will remain in full force and effect as if
the original agreement had been executed without the invalidated, illegal or unenforceable provision. 

  
 17 

	13.13	 Certain Terms. Whenever used in this Agreement, unless otherwise specified: (i) the word
“include” (with its grammatical variations) mean “include, without limitation,” “include but are not limited to”, or words of similar import; (ii) the words “agree” or “written agreement” will
not impose any obligation on Provider or Client to agree to any terms or to engage in discussions relating to such terms, except as such party may elect in such party’s sole discretion; (iii) the word “days” means calendar days;
(iv) the words “copy” and “copies” include, to the extent available, electronic copies, files or databases containing the information, files, items, documents or materials to which such words apply; and (v) all
references to the singular shall include the plural and vice versa. 

  

	13.14	 Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed
an original, but all of which together constitute one and the same instrument. Executed counterparts may be exchanged by facsimile or e-mail in PDF or similar electronic format. 

[Signature page follows] 

  
 18 

 Thus, this Agreement was executed on the date stated in the Introductory clause. 

 

									
	WuXi Biologics (Hong Kong) Limited	 	iTeos Therapeutics SA
					
	By:	 	 /s/ Chris Chen
	 		 	By:	 	 /s/ Michel Detheux

	Name:	 	Chris Chen	 		 	Name:	 	Michel Detheux
	Title:	 	CEO	 		 	Title:	 	Chief Executive Officer
					
		 		 		 		 	 Michel Detheux

On behalf ofMG6A Bioconsulling SPlli, 

Chief Executive Officer
 iTeos
Therapeutics SA

  
 19 

 Exhibit A-Form of Work Order 

WORK ORDER {NUMBER[•]) 
 This work
order is dated[•] and is between[•] (“Client”) and [•][“Provider”). 
 The terms of the
Master Services Agreement between [•) and WuXi Biologics (Hong Kong) Limited, dated [•] (the “Master Services Agreement”), are hereby incorporated by reference into this work order. References in the Master Services
Agreement to the Master Services Agreement will be deemed to be references to this work order with the necessary modifications. Each capitalized term used but not defined in this work order has the meaning given in the Master Services Agreement.

  

	1.	 SERVICES INFORMATION 

 

	1.1	 Title 

{Project title] 
  

	1.2	 Description 

[Description of the Services including deliverables and specifications] 

 

	1.3	 Tasks and Timeframe. Provider shall complete the Services in accordance with the following schedule:

  

			
	 Task
	  	 Completion Date

	1	  	
	2	  	
	3	  	
	4	  	

  

	1.4	 Reporting and Transfer of Data and Results 

[Description of how data and results should be reported and transferred to Client, including electronic protocols for secure transmission of
data and instructions for physical handling and shipping of materials if chemicals are being synthesized or other materials are to be transferred to Client] 

  
 A-1 

	1.5	 Additional Requirements 

[Any additional requirements such as additional obligations of the parties that do not appropriately fit into the task list and special
handling of materials} 
  

	2.	 FEES; PAYMENT SCHEDULE 

 

	2.1	 General Terms. Expenses, milestones, payment and default and other general terms are provided in
Section 3 of the Master Services Agreement. 

  

	2.2	 Service Fee and Upfront Payment. The Service Fee will be CNH[91. On signing of this Work Order,
Client shall pay Provider [91 % of the Service Fee as a non-refundable upfront payment. 

  

	2.3	 Milestones. The table below lists milestones and related information. 

 

							
	 	  	 Milestone
	  	 Deliverable
	  	 Milestone Payment

	1	  	 [Description including work required, criteria for achievement and

timeline]
	  	[91	  	[●]
				
	2	  	[●]	  	[●]	  	

  

	2.4	 Payment Instructions. Unless an invoice provides otherwise, Client shall pay the invoice in CNH by wire
transfer to the account listed below: 

  

			
	Name	  	WuXi Biologics (Hong Kong) Limited
		
	Address	  	Suite 2008, 20/F., Jardine House, 1 Connaught Place, Central, Hong Kong.
		
	Currency	  	CNH
		
	Intermediate Bank:	  	 [***]

		
	Beneficiary Bank	  	 [***]

		
	Beneficiary	  	 [***]

		
	Beneficiary Account	  	 [***]

  
 A-2 

	3.	 COMMUNICATIONS 

 

	3.1	 Technical Communications. All technical communications required under this work order are to be sent via
reputable international courier or email and addressed as follows: 

  
  

			
	If to Client:	  	If to Provider:
		
	[•l	  	[•]
	[•]	  	[•]
	[.•]	  	[•]
	Attn: [•]	  	Attn: [•]
	Tel.: [•]	  	Tel.: [•]
	Email: [•]	  	Email: [•]

 Thus, this work order was executed on the date stated in the introductory clause. 

 

									
	iTeos Therapeutics SA	 	WuXi Biologics (Hong Kong) limited
			
	

	 		 	
				
	By:	 	             
	 	By:	 	  

	Name:	 		 	Name:	 	
	Title:	 		 	Title:	 	
				
		 	Michel Detheux	 		 	
		 	 On bebalfofMG6A Biocommlting SPRL

Chief Executive Officer
 iTeos
Therapeutics SA
	 		 	

  
 A-3 

 Exhibit B-Manufacturing 

 

	1.	 MANUFACTURING AND COMPLIANCE 

 

	1.1	 Specifications and Manufacturing Process. Provider shall manufacture each Product in accordance with the
written specifications for the Product as specified by the Client (the “Specifications”). Client may modify the Specifications; provided, however, that Provider’s consent is required for any modification that would
significantly increase costs. Provider shall negotiate in good faith with Client with the aim of agreeing on a mutually acceptable allocation of the increased costs. 

 

	1.2	 Quality Agreement. This Agreement may incorporate the quality assurance requirements of a quality
agreement (the “Quality Agreement”). If there is a contradiction between a requirement of the Quality Agreement and another provision of this Agreement or a Work Order, then the requirement of the Quality Agreement will take
precedence with respect to quality-related matters, unless this Agreement or the Work Order specifically states that its provision takes precedence. 

  

	1.3	 Regulatory Assistance. Provider shall, at Client’s cost, provide Client with all supporting data
and information relating to manufacturing of the Product that is reasonably necessary for obtaining and maintaining regulatory approvals relating to the Product, including any documentation which is or is equivalent to the FDA’s Chemistry and
Manufacturing Controls related to any marketing authorization. 

  

	2.	 QUALITY RELEASE AND DELIVERY 

 

	2.1	 Quality Release. Product may not be delivered to Client until a person authorized by Client having the
necessary qualifications, experience and authority to oversee quality assurance of the manufacture and determine the suitability of individual batches for release under Applicable Law has (a) conducted analyses using the analytical methods
agreed to in writing by the parties, (b) executed the Certificate of Analysis (i.e., the written test results of a batch that is tested against the applicable criteria in the Specifications, and confirmation the batch passed the test)
applicable to the Product and such other batch documentation that may be requested by Client and (c) completed any other certifications or documents and other activities that may be required to release the Product under Applicable Law and the
Quality Agreement. Notwithstanding the foregoing, at Client’s request, Provider may deliver Product in quarantine prior to delivery of the Certificate of Analysis. The request must be accompanied by Client’s written acknowledgement that
(a) the Product has been delivered without a Certificate of Analysis, (bl accordingly, the Product cannot be administered to humans until transmittal of the Certificate of Analysis and (c) that Client nevertheless accepts full risk of
loss, title and ownership of the Product. The delivery of Product In quarantine will be subject to such testing requirements as Provider may reasonably require. 

  
 B-1 

	2.2	 Delivery. Provider shall ship the Product in accordance with Section 12 of the main body of the
Agreement. 

  

	2.3	 Acceptance; Damage. Client shall diligently examine the Product as soon as practicable after receipt.
Client shall notify Provider (a) within [***] for claims relating to visible damage of the shipping containers or materials, and (b) within [***] after Provider’s dispatch notice for claims relating to
non-delivery. Client shall make damaged Product and packaging materials available for inspection and comply with reasonable requirements of any insurance policy covering the Product. 

 

	3.	 NON-CONFORMING PRODUCT 

 

	3.1	 Warranty. Provider warrants to Client that each Product supplied will have been manufactured in accordance
with, and will comply with, this Agreement, its Work Order, the Specifications, cGMP and Applicable Law (the “Warranty”). 

  

	3.2	 Non-Conformance. Client may only reject a shipment of a Product
if, within [***] after receiving the shipment (or, in the case of Latent Defects, within [***] after discovery thereof by Client), (a) Client conducts a quality inspection and determines that the Product does not conform to the Warranty,
(b) notifies Provider in writing that the Product does not conform and (c) provides supporting documentation. A shipment that is not rejected pursuant to the preceding sentence will be deemed accepted by Client. “Latent
Defect” means any defect that is not normally detected by visual inspection or the analytical methods used to characterize the Product at the time of release. [***] 

 

	3.3	 Disputes. If the parties are unable to agree as to whether a Product conforms to the Warranty, Client
shall send a sample of the Product for testing at an independent quality control laboratory chosen by Provider and reasonably acceptable to Client. The findings of the laboratory will be binding on the parties. The cost of inspections and testing by
the laboratory will be borne equally by each party. 

  

	3.4	 [***] 

  
 B-2 

	4.	 RECALLS 

  

	4.1	 [***] 

  

	4.2	 [***] 

  

	4.3	 [***] 

  

  
 8-2EX-10.5

 Exhibit 10.5 

ITEOS THERAPEUTICS, INC. 

2020 EMPLOYEE STOCK PURCHASE PLAN 

The purpose of the iTeos Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of iTeos
Therapeutics, Inc. (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). 317,484
shares of Common Stock in the aggregate have been approved and reserved for this purpose, plus on January 1, 2021 and each January 1 thereafter until the Plan terminates pursuant to Section 20, the number of shares of Common Stock
reserved and available for issuance under the Plan shall be cumulatively increased by the lesser of (i) 634,969 shares of Common Stock, (ii) 1 percent of the number of shares of Common Stock issued and outstanding on the immediately preceding
December 31, or (iii) such lesser number of shares of Common Stock as determined by the Administrator (as defined in Section 1). 

The Plan includes two components: a Code Section 423 Component (the “423 Component”) and a
non-Code Section 423 Component (the “Non-423 Component”). It is intended for the 423 Component to constitute an “employee stock purchase plan”
within the meaning of Section 423(b) of the Internal Revenue Code of 1986, as amended (the “Code”), and the 423 Component shall be interpreted in accordance with that intent. Under the Non-423
Component, which does not qualify as an “employee stock purchase plan” within the meaning of Section 423(b) of the Code, options will be granted pursuant to rules, procedures or sub-plans
adopted by the Administrator designed to comply with applicable laws or achieve tax and other objectives. Except as otherwise provided herein or by the Administrator, the Non-423 Component will operate and be
administered in the same manner as the 423 Component. 

 Unless otherwise defined herein, capitalized terms in this Plan shall have the meaning
ascribed to them in Section 11. 
 1. Administration. The Plan will be administered by the person or persons (the
“Administrator”) appointed by the Company’s Board of Directors (the “Board”) for such purpose. The Administrator has authority at any time to: (i) adopt, alter and repeal such rules, guidelines and practices for the
administration of the Plan and for its own acts and proceedings as it shall deem advisable; (ii) interpret the terms and provisions of the Plan; (iii) make all determinations it deems advisable for the administration of the Plan, including
to accommodate the specific requirements of applicable laws, regulations and procedures in jurisdictions outside the United States; (iv) decide all disputes arising in connection with the Plan; and (v) otherwise supervise the
administration of the Plan. All interpretations and decisions of the Administrator shall be binding on all persons, including the Company and the Participants. No member of the Board or individual exercising administrative authority with respect to
the Plan shall be liable for any action or determination made in good faith with respect to the Plan or any option granted hereunder. 
 2.
Offerings. The Company may make one or more offerings to eligible employees to purchase Common Stock under the Plan (“Offerings”). The initial Offering will begin and end on dates to be determined by the Administrator (the
“Initial Offering”). Thereafter, unless otherwise determined by the Administrator, an Offering will begin on the first business day occurring on or after each January 1st and July 1st and will end on the last business day occurring on or
before the following June 30th and December 31st, respectively. The Administrator may, in its discretion, designate a different period for any Offering, provided that no Offering shall exceed 27 months in duration or overlap with any other Offering.

  
 2 

 3. Eligibility. Except as otherwise determined by the Administrator in advance of an
Offering, all individuals classified as employees on the payroll records of the Company and each Designated Company are eligible to participate in any one or more of the Offerings under the Plan. The Administrator may further determine, in advance
of an Offering, that employees are eligible only if, as of the first day of the applicable Offering (the “Offering Date”), they are customarily employed by the Company or a Designated Company for more than 20 hours a week, provided,
however, that employees who are employed for 20 hours or less a week may be eligible to participate in the Plan if required by applicable law or regulations. Notwithstanding any other provision herein, individuals who are not contemporaneously
classified as employees of the Company or a Designated Company for purposes of the Company’s or applicable Designated Company’s payroll system are not considered to be eligible employees of the Company or any Designated Company and shall
not be eligible to participate in the Plan. In the event any such individuals are reclassified as employees of the Company or a Designated Company for any purpose, including, without limitation, common law or statutory employees, by any action of
any third party, including, without limitation, any government agency, or as a result of any private lawsuit, action or administrative proceeding, such individuals shall, notwithstanding such reclassification, remain ineligible for participation.
Notwithstanding the foregoing, the exclusive means for individuals who are not contemporaneously classified as employees of the Company or a Designated Company on the Company’s or Designated Company’s payroll system to become eligible to
participate in this Plan is through an amendment to this Plan, duly executed by the Company, which specifically renders such individuals eligible to participate herein. 

  
 3 

 4. Participation. 

(a) An eligible employee who is not a Participant in any prior Offering may participate in a subsequent Offering by submitting an enrollment
form to the Company or an agent designated by the Company (in the manner described in Section 4(c)) at least 15 business days before the Offering Date (or by such other deadline as shall be established by the Administrator for the Offering).

 (b) Enrollment. The enrollment form (which may be in an electronic format or such other method as determined by the Company in
accordance with the Company’s practices) will (a) state a whole percentage to be deducted from an eligible employee’s Compensation (as defined in Section 11) per pay period, (b) authorize the purchase of Common Stock in each
Offering in accordance with the terms of the Plan and (c) specify the exact name or names in which shares of Common Stock purchased for such individual are to be issued pursuant to Section 10. An employee who does not enroll in accordance
with these procedures will be deemed to have waived the right to participate. Unless a Participant files a new enrollment form or withdraws from the Plan, such Participant’s deductions and purchases will continue at the same percentage of
Compensation for future Offerings, provided he or she remains eligible. 
 (c) Notwithstanding the foregoing, participation in the Plan will
neither be permitted nor be denied contrary to the requirements of the Code. 
 5. Employee Contributions. Each eligible employee may
authorize payroll deductions at a minimum of 1 percent up to a maximum of 15 percent of such employee’s Compensation for each pay period or such other maximum as may be specified by the Administrator in advance of an Offering. The
Company will maintain book accounts showing the amount of payroll deductions made by each Participant for each Offering. No interest will accrue or be paid on payroll 

  
 4 

 
deductions, except as may be required by applicable law. If payroll deductions for purposes of the Plan are prohibited or otherwise problematic under applicable law (as determined by the
Administrator in its discretion), the Administrator may require Participants to contribute to the Plan by such other means as determined by the Administrator. Any reference to “payroll deductions” in this Section 5 (or in any other
section of the Plan) will similarly cover contributions by other means made pursuant to this Section 5. 
 6. Deduction Changes.
Except as may be determined by the Administrator in advance of an Offering, a Participant may not increase or decrease his or her payroll deduction during any Offering, but may increase or decrease his or her payroll deduction with respect to the
next Offering (subject to the limitations of Section 5) by filing a new enrollment form at least 15 business days before the next Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). The
Administrator may, in advance of any Offering, establish rules permitting a Participant to increase, decrease or terminate his or her payroll deduction during an Offering. 

7. Withdrawal. A Participant may withdraw from participation in the Plan by delivering a written notice of withdrawal to the Company or
an agent designated by the Company (in accordance with such procedures and such timing as may be established by the Administrator). The Participant’s withdrawal will be effective as of the next business day. Following a Participant’s
withdrawal, the Company will promptly refund such individual’s entire account balance under the Plan to him or her (after payment for any Common Stock purchased before the effective date of withdrawal). Partial withdrawals are not permitted.
Such an employee may not begin participation again during the remainder of the Offering, but may enroll in a subsequent Offering in accordance with Section 4. 

  
 5 

 8. Grant of Options. On each Offering Date, the Company will grant to each eligible
employee who is then a Participant in the Plan an option (“Option”) to purchase on the last day of such Offering (the “Exercise Date”), at the Option Price (as defined herein), the lowest of (a) a number of shares of Common
Stock determined by dividing such Participant’s accumulated payroll deductions on such Exercise Date by the Option Price (as defined herein), (b) 5,000 shares; or (c) such other lesser maximum number of shares as shall have been
established by the Administrator in advance of the Offering; provided, however, that such Option shall be subject to the limitations set forth below. Each Participant’s Option shall be exercisable only to the extent of such Participant’s
accumulated payroll deductions on the Exercise Date. The purchase price for each share purchased under each Option (the “Option Price”) will be 85 percent of the Fair Market Value of the Common Stock on the Offering Date or the
Exercise Date, whichever is less. 
 Notwithstanding the foregoing, no Participant may be granted an Option hereunder if such Participant,
immediately after the Option was granted, would be treated as owning stock possessing 5 percent or more of the total combined voting power or value of all classes of stock of the Company or any Parent or Subsidiary. For purposes of the
preceding sentence, the attribution rules of Section 424(d) of the Code shall apply in determining the stock ownership of a Participant, and all stock which the Participant has a contractual right to purchase shall be treated as stock owned by
the Participant. In addition, no Participant may be granted an Option which permits his or her rights to purchase stock under the Plan, and any other employee stock purchase plan of the Company and its Parents and Subsidiaries, to accrue at a rate
which exceeds $25,000 of the fair market value of such stock (determined on the option grant date or dates) for each calendar year in which the Option is outstanding at any time. The purpose of the limitation in the preceding sentence is to comply
with Section 423(b)(8) of the Code and shall be applied taking Options into account in the order in which they were granted. 

  
 6 

 9. Exercise of Option and Purchase of Shares. Each employee who continues to be a
Participant in the Plan on the Exercise Date shall be deemed to have exercised his or her Option on such date and shall acquire from the Company such number of whole shares of Common Stock reserved for the purpose of the Plan (or, if delivery of
shares is determined by the Administrator in its sole discretion to be problematic under applicable law, the Participant shall receive a cash amount equal to the Fair Market Value on the Exercise Date of such whole number of shares of Common Stock)
as his or her accumulated payroll deductions on such date will purchase at the Option Price, subject to any other limitations contained in the Plan. Unless otherwise determined by the Administrator in advance of an Offering, any amount remaining in
a Participant’s account at the end of an Offering solely by reason of the inability to purchase a fractional share will be carried forward to the next Offering; any other balance remaining in a Participant’s account at the end of an
Offering will be refunded to the Participant promptly. 
 10. Issuance of Certificates. Certificates or book-entries at the
Company’s transfer agent representing shares of Common Stock purchased under the Plan may be issued only in the name of the employee, in the name of the employee and another person of legal age as joint tenants with rights of survivorship, or
in the name of a broker authorized by the employee to be his, her or their, nominee for such purpose. 
 11. Definitions. 

The term “Affiliate” means any entity that, directly or indirectly through one or more intermediaries, controls, is controlled by or
is under the common control with the Company. 

  
 7 

 The term “Compensation” means the amount of total cash compensation, prior to
salary reduction pursuant to Sections 125, 132(f) or 401(k) of the Code, including base pay, overtime, commissions, and incentive or bonus awards, but excluding allowances and reimbursements for expenses such as relocation allowances or travel
expenses, income or gains related to Company stock options or other share-based awards, and similar items. The Administrator shall have the discretion to determine the application of this definition to Participants outside the United States. 

The term “Designated Company” means any present or future Subsidiary that has been designated by the Administrator to participate in
the Plan. The Administrator may so designate any Subsidiary or Affiliate, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved by the stockholders, and may further designate such companies or
Participants as participating in the 423 Component or the Non-423 Component. The Administrator may also determine which affiliates or eligible employees may be excluded from participation in the Plan, to the
extent consistent with Section 423 of the Code or as implemented under the Non-423 Component, and determine which Designated Company or Companies will participate in separate Offerings (to the extent that
the Company makes separate Offerings). For purposes of the 423 Component, only the Company and its Subsidiaries may be Designated Companies; provided, however, that at any given time, a Subsidiary that is a Designated Company under the 423 Component
will not be a Designated Company under the Non-423 Component. The current list of Designated Companies is attached hereto as Appendix A. 

The term “Fair Market Value of the Common Stock” on any given date means the fair market value of the Common Stock determined in
good faith by the Administrator; provided, however, that if the Common Stock is admitted to quotation on The Nasdaq Global Market or another national securities exchange, the determination shall be made by reference to the closing price on such
date. If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which there is a closing price. 

  
 8 

 The term “Initial Public Offering” means the first underwritten, firm commitment
public offering pursuant to an effective registration statement under the U.S. Securities Act of 1933, as amended, covering the offer and sale by the Company of its Common Stock. 

The term “Parent” means a “parent corporation” with respect to the Company, as defined in Section 424(e) of the Code.

 The term “Participant” means an individual who is eligible as determined in Section 3 and who has complied with the
provisions of Section 4. 
 The term “Registration Date” means the date on which the registration statement on Form S-1 that is filed by the Company with respect to its Initial Public Offering is declared effective by the U.S. Securities and Exchange Commission (the “SEC”). 

The term “Subsidiary” means a “subsidiary corporation” with respect to the Company, as defined in Section 424(f) of
the Code. 
 12. Rights on Termination or Transfer of Employment. If a Participant’s employment terminates for any reason before
the Exercise Date for any Offering, no payroll deduction will be taken from any pay due and owing to the Participant and the balance in the Participant’s account will be paid to such Participant or, in the case of such Participant’s death,
if permitted by the Administrator and valid under applicable law, to his or her designated beneficiary or to the legal representative of his or her estate as if such Participant had withdrawn from the Plan under Section 7. An employee will be
deemed to have terminated employment, for this purpose, if the corporation that employs him or her, having been a Designated Company, ceases to be a Subsidiary or Affiliate, or if the employee is transferred to any corporation other than the Company
or a 

  
 9 

 
Designated Company. Unless otherwise determined by the Administrator, a Participant whose employment transfers between, or whose employment terminates with an immediate rehire (with no break in
service) by, Designated Companies or a Designated Company and the Company will not be treated as having terminated employment for purposes of participating in the Plan or an Offering; provided, however, that if a Participant transfers from an
Offering under the 423 Component to an Offering under the Non-423 Component, the exercise of the Participant’s Option will be qualified under the 423 Component only to the extent that such exercise
complies with Section 423 of the Code. If a Participant transfers from an Offering under the Non-423 Component to an Offering under the 423 Component, the exercise of the Participant’s Option will
remain non-qualified under the Non-423 Component. Further, an employee will not be deemed to have terminated employment for purposes of this Section 12, if the
employee is on an approved leave of absence where the employee’s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise
provides in writing. 
 13. Special Rules and Sub-Plans. Notwithstanding anything herein to
the contrary, the Administrator may adopt special rules or sub-plans applicable to the employees of a particular Designated Company, whenever the Administrator determines that such rules are necessary or
appropriate for the implementation of the Plan in a jurisdiction where such Designated Company has employees, regarding, without limitation, eligibility to participate in the Plan, handling and making of payroll deductions or contributions by other
means, establishment of bank or trust accounts to hold payroll deductions, payment of interest, conversion of local currency, obligation to pay payroll tax, withholding procedures and handling of share issuances, any of which may vary according to
applicable requirements; provided that if such special rules or sub-plans are inconsistent with the requirements of Section 423(b) of the Code the employees subject to such special rules or sub-plans will participate in the Non-423 Component. 

  
 10 

 14. Optionees Not Stockholders. Neither the granting of an Option to a Participant
nor the deductions from his or her pay shall result in such Participant becoming a holder of the shares of Common Stock covered by an Option under the Plan until such shares have been purchased by and issued to him or her. 

15. Rights Not Transferable. Rights under the Plan are not transferable by a Participant other than by will or the laws of descent and
distribution, and are exercisable during the Participant’s lifetime only by the Participant. 
 16. Application of Funds. All
funds received or held by the Company under the Plan may be combined with other corporate funds and may be used for any corporate purpose, unless otherwise required under applicable law. 

17. Adjustment in Case of Changes Affecting Common Stock. In the event of a subdivision of outstanding shares of Common Stock, the
payment of a dividend in Common Stock or any other change affecting the Common Stock, the number of shares approved for the Plan and the share limitation set forth in Section 8 shall be equitably or proportionately adjusted to give proper
effect to such event. 
 18. Amendment of the Plan. The Board may at any time and from time to time amend the Plan in any respect,
except that without the approval within 12 months of such Board action by the stockholders, no amendment shall be made increasing the number of shares approved for the 423 Component of the Plan or making any other change that would require
stockholder approval in order for the Plan, as amended, to qualify as an “employee stock purchase plan” under Section 423(b) of the Code. 

  
 11 

 19. Insufficient Shares. If the total number of shares of Common Stock that would
otherwise be purchased on any Exercise Date plus the number of shares purchased under previous Offerings under the Plan exceeds the maximum number of shares issuable under the Plan, the shares then available shall be apportioned among Participants
in proportion to the amount of payroll deductions accumulated on behalf of each Participant that would otherwise be used to purchase Common Stock on such Exercise Date. 

20. Termination of the Plan. The Plan may be terminated at any time by the Board. Upon termination of the Plan, all amounts in the
accounts of Participants shall be promptly refunded. Unless terminated earlier, the Plan shall automatically terminate on the ten year anniversary of the Effective Date. 

21. Compliance with Law. The Company’s obligation to sell and deliver Common Stock under the Plan is subject to applicable laws and
the completion of any registration or qualification of the Common Stock under any U.S. or non-U.S. local, state or federal securities or exchange control law, or under rulings or regulations of the SEC or of
any other governmental regulatory body, and to obtaining any approval or other clearance from any U.S. and non-U.S. local, state or federal governmental agency, which registration, qualification or approval
the Company shall, in its absolute discretion, deem necessary or advisable. The Company is under no obligation to register or qualify the Common Stock with the SEC or any other U.S. or non-U.S. securities
commission or to seek approval or clearance from any governmental authority for the issuance or sale of such stock. 
 22. Governing
Law. This Plan and all Options and actions taken thereunder shall be governed by, and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be
governed by and construed in accordance with the internal laws of the State of Commonwealth of Massachusetts applied without regard to conflict of law principles. 

  
 12 

 23. Issuance of Shares. Shares may be issued upon exercise of an Option from
authorized but unissued Common Stock, from shares held in the treasury of the Company, or from any other proper source. 
 24. Tax
Withholding. Participation in the Plan is subject to any applicable U.S. and non-U.S. federal, state or local tax withholding requirements on income the Participant realizes in connection with the Plan.
Each Participant agrees, by entering the Plan, that the Company or any Subsidiary or Affiliate may withhold from a Participant’s wages, salary or other compensation at any time the amount necessary for the Company or any Subsidiary or Affiliate
to meet applicable withholding obligations, including any withholding required to make available to the Company or any Subsidiary or Affiliate any tax deductions or benefits attributable to the sale or disposition of Common Stock by such
Participant. In addition, the Company or any Subsidiary or Affiliate may withhold from the proceeds of the sale of Common Stock or use any other method of withholding that the Company or any Subsidiary or Affiliate deems appropriate to the extent
permitted by U.S. Treasury Regulation Section 1.423-2(f) with respect to the 423 Component. The Company will not be required to issue any Common Stock under the Plan until such obligations are satisfied.

 25. Notification Upon Sale of Shares under the 423 Component. Each Participant agrees, by entering the 423 Component of the Plan,
to give the Company prompt notice of any disposition of shares purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such shares were purchased or within one year after the
date such shares were purchased. 

  
 13 

 26. Effective Date and Approval of Shareholders. The Plan shall take effect on the
date immediately preceding the Registration Date, subject to approval by the holders of a majority of the votes cast at a meeting of stockholders at which a quorum is present or by written consent of the stockholders. 

DATE APPROVED BY BOARD OF DIRECTORS: 
 DATE APPROVED
BY STOCKHOLDERS: 

  
 14 

 APPENDIX A 

Designated Companies 

  
 15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]